The Column Group
VC · San Francisco · United States
Stages
Investment region
Industries
Profile
The Column Group (TCG) is a venture capital firm based in San Francisco, California, founded in 2007 by Peter Svennilson. The firm focuses on early-stage investments in the life sciences sector, particularly in biotechnology and drug discovery. TCG is known for its unique approach to venture capital, emphasizing long-term investments and company formation rather than quick exits. The team comprises 23 professionals, including partners with deep scientific and financial expertise. TCG invests primarily in the United States, targeting sectors such as healthcare, life sciences, oncology, and technology-based industries. The firm operates an ecosystem of funds, including TCG Platform funds, TCG Opportunity funds, and TCG Labs-Soleil, which support technology platforms and later-stage programs. TCG has generated $4 billion in returns for its partners and manages several funds, including The Column Group IV and The Column Group Opportunity III. Notable portfolio companies include Carmot Therapeutics - drug discovery, Peloton Therapeutics - oncology, Aragon Pharmaceuticals - prostate cancer treatments, Neurona Therapeutics - cell therapy, and Constellation Pharmaceuticals - epigenetics. TCG's investments have led to 18 successful exits, showcasing its impact on the biotech industry.
Kontakte (2)
| Name | Title | Telefon | ||
|---|---|---|---|---|
| Founder / Managing Partner | — | — | — | |
| Managing Partner | — | — | — |
Name, email and phone are partially hidden. Subscribe to see them in full.